UT Horizon Fund
VC Fund
Austin, United States
UT Horizon Fund is a VC fund in Austin focused on Health Care and Biotechnology. Founded in 2012, the UT Horizon Fund is the strategic fund of the University of Texas System. Based on cutting edge research at UT System institutions, the UT Horizon Fund works with entrepreneurs and the investment community to help translate innovations out of UT to practical use. The UT Horizon Fund is evergreen where returns are re-investedfor future growth and development.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries UT Horizon Fund invests in
Stages UT Horizon Fund invests in
Countries UT Horizon Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Matt Sorenson
|
|||
Suruchi Parwal
|
|||
Gus Johnson
|
|||
Investment Focus
Industry
- Health Care 12 (36%)
- Biotechnology 8 (24%)
- Medical 6 (18%)
- Medical Device 5 (15%)
- Therapeutics 4 (12%)
Stage
- Series A 8 (24%)
- Convertible Note 6 (18%)
- Seed 5 (15%)
- Series B 4 (12%)
- Series C 4 (12%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Matt Sorenson
Investment Analyst
|
Investment Analyst | Total investments: 0 | Find email | |
|
Suruchi Parwal
Senior Investment Analyst
|
Senior Investment Analyst | Total investments: 0 | Find email | |
|
Gus Johnson
Assistant Director
|
Assistant Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cerebri AI Inc.
|
Cerebri AI provides customers with "Answers-as-a-Service" using our CVX 3 real-time AI software platform. Everyone needs answers, and increasingly AI provides them. Our break-through CVX 3 AI platform incorporates real-time data and batch data - from IT, IoT, streaming sources - and provides up to the second data & engineeredfeatures updates used in our robust models for propensity, affinity, engagement, and actions.. We provide rapid service and best-in-class real-time Answers for important time series-based problems such as CX ( customer churn, up-selling, etc. ), workforce management ( employee attrition, etc. ), etc.. if it is a time series we can provide answers for your business or for software companies looking for advanced analytics for customers. | $7M / Convertible Note / Dec 04, 2019 | |
|
Cerebri AI Inc.
|
Cerebri AI provides customers with "Answers-as-a-Service" using our CVX 3 real-time AI software platform. Everyone needs answers, and increasingly AI provides them. Our break-through CVX 3 AI platform incorporates real-time data and batch data - from IT, IoT, streaming sources - and provides up to the second data & engineeredfeatures updates used in our robust models for propensity, affinity, engagement, and actions.. We provide rapid service and best-in-class real-time Answers for important time series-based problems such as CX ( customer churn, up-selling, etc. ), workforce management ( employee attrition, etc. ), etc.. if it is a time series we can provide answers for your business or for software companies looking for advanced analytics for customers. | $5M / Jun 28, 2018 | |
|
Cerebri AI Inc.
|
Cerebri AI provides customers with "Answers-as-a-Service" using our CVX 3 real-time AI software platform. Everyone needs answers, and increasingly AI provides them. Our break-through CVX 3 AI platform incorporates real-time data and batch data - from IT, IoT, streaming sources - and provides up to the second data & engineeredfeatures updates used in our robust models for propensity, affinity, engagement, and actions.. We provide rapid service and best-in-class real-time Answers for important time series-based problems such as CX ( customer churn, up-selling, etc. ), workforce management ( employee attrition, etc. ), etc.. if it is a time series we can provide answers for your business or for software companies looking for advanced analytics for customers. | $5M / Series A / Jun 28, 2018 | |
GenXComm
|
GenXComm's robust Simultaneous Self Interference Cancellation (S-SIX) Technology enables maximal use of available spectrum just as carriers are planning their 5G cellular network deployments to cope with a flood of new wireless devices and rapidly increasing data demands on their networks. Today, communications between wireless transceiversuse multiple frequencies (FDD) or time slots (TDD). GenXComm’s S-SIX technology enables true full duplex or simultaneous transmission and reception of signals in the same channel. The value proposition of GenXComm’s technology goes well beyond just enabling true full duplex, and can improve the throughput of the network by over an order of magnitude. S-SIX also significantly reduces the latency and improves network adaptability and security. GenXComm’s S-SIX is a key enabling technology for an increasingly connected world. | $7M / Series A / Dec 12, 2017 | |
Cardiovate
|
Cardiovate is a medical technology company that targets transformational health care opportunities in tissue regeneration and repair. | $1M / Seed / Nov 21, 2017 | |
Astrocyte Pharmaceuticals
|
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $2.4M / Seed / Jul 17, 2017 | |
|
GenXComm
|
GenXComm's robust Simultaneous Self Interference Cancellation (S-SIX) Technology enables maximal use of available spectrum just as carriers are planning their 5G cellular network deployments to cope with a flood of new wireless devices and rapidly increasing data demands on their networks. Today, communications between wireless transceiversuse multiple frequencies (FDD) or time slots (TDD). GenXComm’s S-SIX technology enables true full duplex or simultaneous transmission and reception of signals in the same channel. The value proposition of GenXComm’s technology goes well beyond just enabling true full duplex, and can improve the throughput of the network by over an order of magnitude. S-SIX also significantly reduces the latency and improves network adaptability and security. GenXComm’s S-SIX is a key enabling technology for an increasingly connected world. | $1.5M / Seed / Jun 20, 2017 | |
Lung Therapeutics
|
Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a debilitating condition where fluid has built up in the chest cavity surrounding the lungs andfibrinous scar tissue in the pleural cavity blocks fluid drainage. Their first product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is being studied for safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. By clearing the fibrinous buildup pharmaceutically, the clinical pathway for these patients is significantly improved, enabling simple draining of pleural fluid without surgery. Their longer-term efforts will target improvement of clinical pathways for Acute Lung Injury, Idiopathic Pulmonary Fibrosis and other disease conditions. | $14.3M / Series B / Jun 06, 2017 | |
|
Astrocyte Pharmaceuticals
|
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $1.4M / Seed / Mar 24, 2017 | |
Alafair Biosciences
|
Alafair Biosciences develops cross-linked polysaccharide hydrogel films for the post-surgical complication of adhesion or tethering between opposing tissue surfaces. It focuses on the development of membranes, bilayers, and injectable gel solutions for anti-adhesion, wound care, and tissue reconstruction applications. The company was founded in2011 and is based in Austin, Texas. | $2M / Series A / Aug 09, 2016 | |
| See all 33 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does UT Horizon Fund invest in?
UT Horizon Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Convertible Note stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact UT Horizon Fund?
Public channels for UT Horizon Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UT Horizon Fund?
The team at UT Horizon Fund includes Matt Sorenson (Investment Analyst), Suruchi Parwal (Senior Investment Analyst) and Gus Johnson (Assistant Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
